Suppr超能文献

用于下肢静脉溃疡的抗生素和防腐剂

Antibiotics and antiseptics for venous leg ulcers.

作者信息

O'Meara Susan, Al-Kurdi Deyaa, Ologun Yemisi, Ovington Liza G

机构信息

Department of Health Sciences, University of York, Area 3 Seebohm Rowntree Building, Heslington, York, UK, YO10 5DD.

出版信息

Cochrane Database Syst Rev. 2010 Jan 20(1):CD003557. doi: 10.1002/14651858.CD003557.pub3.

Abstract

BACKGROUND

Venous leg ulcers are a type of chronic wound affecting up to 1% of adults in developed countries at some point during their lives. Many of these wounds are colonised by bacteria or show signs of clinical infection. The presence of infection may delay ulcer healing. There are two main strategies used to prevent and treat clinical infection in venous leg ulcers: systemic antibiotics and topical antibiotics or antiseptics.

OBJECTIVES

The objective of the review is to determine the effects of systemic antibiotics, topical antibiotics and antiseptics on the healing of venous ulcers.

SEARCH STRATEGY

For the update of this review we searched the Cochrane Wounds Group Specialised Register (searched 24/09/09); The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library 2009 Issue 3; Ovid MEDLINE - 1950 to September Week 3 2009; Ovid EMBASE - 1980 to 2009 Week 38; and EBSCO CINAHL - 1982 to September Week 3 2009. No language or publication date restrictions were applied.

SELECTION CRITERIA

Randomised controlled trials recruiting people with venous leg ulceration and evaluating at least one systemic antibiotic, topical antibiotic or topical antiseptic that reported an objective assessment of wound healing (e.g. time to complete healing, frequency of complete healing, change in ulcer surface area) were eligible for inclusion. Selection decisions were made by two authors working independently.

DATA COLLECTION AND ANALYSIS

Information on the characteristics of participants, interventions and outcomes were recorded on a standardised data extraction form. In addition, aspects of trial methods were extracted, including randomisation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data and study group comparability at baseline. Data extraction and validity assessment were conducted by one author and checked by a second.

MAIN RESULTS

Twenty five trials reporting 32 comparisons were identified. Five trials evaluated systemic antibiotics; the remainder evaluated topical preparations: cadexomer iodine (10 trials); povidone iodine (5 trials); peroxide-based preparations (3 trials); ethacridine lactate (1 trial); mupirocin (1 trial); and chlorhexidine (1 trial). For the systemic antibiotics, the only comparison where a statistically significant between-group difference was detected was that in favour of the antihelminthic levamisole when compared with placebo. This trial, in common with the other evaluations of systemic antibiotics, was small and so the observed effect could have occurred by chance or been due to baseline imbalances in prognostic factors. For topical preparations, there is some evidence to suggest that cadexomer iodine generates higher healing rates than standard care. One study showed a statistically significant result in favour of cadexomer iodine when compared with standard care (not involving compression) in the frequency of complete healing at six weeks (RR 2.29, 95% CI 1.10 to 4.74). The intervention regimen used was intensive, involving daily dressing changes, and so these findings may not be generalisable to most everyday clinical settings. When cadexomer iodine was compared with standard care with all patients receiving compression, the pooled estimate from two trials for frequency of complete healing at 4 to 6 weeks indicated significantly higher healing rates for cadexomer iodine (RR 6.72, 95% CI 1.56 to 28.95). Surrogate healing outcomes such as change in ulcer surface area and daily or weekly healing rate showed favourable results for cadexomer iodine, peroxide-based preparations and ethacridine lactate in some studies. These surrogate outcomes may not be valid proxies for complete healing of the wound. Most of the trials were small and many had methodological problems such as poor baseline comparability between groups, failure to use (or report) true randomisation, adequate allocation concealment, blinded outcome assessment and analysis by intention-to-treat.

AUTHORS' CONCLUSIONS: At present, there is no evidence to support the routine use of systemic antibiotics to promote healing in venous leg ulcers. However, the lack of reliable evidence means that it is not possible to recommend the discontinuation of any of the agents reviewed. In terms of topical preparations, there is some evidence to support the use of cadexomer iodine. Further good quality research is required before definitive conclusions can be made about the effectiveness of systemic antibiotics and topical preparations such as povidone iodine, peroxide-based preparations, ethacridine lactate, mupirocin and chlorhexidine in healing venous leg ulceration. In light of the increasing problem of bacterial resistance to antibiotics, current prescribing guidelines recommend that antibacterial preparations should only be used in cases of clinical infection and not for bacterial colonisation.

摘要

背景

腿部静脉溃疡是一种慢性伤口,在发达国家,多达1%的成年人在其一生中的某个阶段会受到影响。这些伤口中有许多被细菌定植或出现临床感染迹象。感染的存在可能会延迟溃疡愈合。预防和治疗腿部静脉溃疡临床感染主要有两种策略:全身用抗生素和局部用抗生素或防腐剂。

目的

本综述的目的是确定全身用抗生素、局部用抗生素和防腐剂对静脉溃疡愈合的影响。

检索策略

为更新本综述,我们检索了Cochrane伤口小组专业注册库(检索日期为2009年9月24日);Cochrane对照试验中央注册库(CENTRAL)——Cochrane图书馆2009年第3期;Ovid MEDLINE——1950年至2009年第3周;Ovid EMBASE——1980年至2009年第38周;以及EBSCO CINAHL——1982年至2009年第3周。未设语言或出版日期限制。

入选标准

纳入招募腿部静脉溃疡患者并评估至少一种全身用抗生素、局部用抗生素或局部用防腐剂的随机对照试验,这些试验报告了对伤口愈合的客观评估(如完全愈合时间、完全愈合频率、溃疡表面积变化)。由两位独立工作的作者做出入选决定。

数据收集与分析

关于参与者特征、干预措施和结果的信息记录在标准化的数据提取表上。此外,提取试验方法的各个方面,包括随机化、分配隐藏、参与者和结果评估者的盲法、不完整的结果数据以及基线时研究组的可比性。数据提取和有效性评估由一位作者进行,另一位作者进行核对。

主要结果

共识别出25项试验,报告了32项比较。5项试验评估了全身用抗生素;其余试验评估了局部制剂:卡地姆碘(10项试验);聚维酮碘(5项试验);过氧化物类制剂(3项试验);乳酸依沙吖啶(1项试验);莫匹罗星(1项试验);以及氯己定(1项试验)。对于全身用抗生素,唯一检测到组间有统计学显著差异的比较是,与安慰剂相比,抗蠕虫药左旋咪唑具有优势。与其他全身用抗生素评估一样,该试验规模较小,因此观察到的效果可能是偶然发生的,或者是由于预后因素的基线不平衡所致。对于局部制剂,有一些证据表明卡地姆碘产生的愈合率高于标准护理。一项研究显示,与标准护理(不包括加压)相比,卡地姆碘在六周时完全愈合频率方面有统计学显著优势(RR 2.29,95%CI 1.10至4.74)。所采用的干预方案较为密集,包括每天更换敷料,因此这些结果可能不适用于大多数日常临床环境。当将卡地姆碘与所有患者均接受加压的标准护理进行比较时,两项试验对4至6周时完全愈合频率的合并估计表明,卡地姆碘的愈合率显著更高(RR 6.72,95%CI 1.56至28.95)。在一些研究中,诸如溃疡表面积变化以及每日或每周愈合率等替代愈合结果显示卡地姆碘、过氧化物类制剂和乳酸依沙吖啶有良好结果。这些替代结果可能并非伤口完全愈合的有效替代指标。大多数试验规模较小,许多试验存在方法学问题,如组间基线可比性差、未采用(或报告)真正的随机化、充分的分配隐藏、盲法结果评估以及意向性分析。

作者结论

目前,没有证据支持常规使用全身用抗生素促进腿部静脉溃疡愈合。然而,缺乏可靠证据意味着无法建议停用所审查的任何药物。就局部制剂而言,有一些证据支持使用卡地姆碘。在能够就全身用抗生素以及聚维酮碘、过氧化物类制剂、乳酸依沙吖啶、莫匹罗星和氯己定等局部制剂在愈合腿部静脉溃疡方面的有效性得出明确结论之前,还需要进一步的高质量研究。鉴于抗生素耐药性问题日益严重,当前的处方指南建议抗菌制剂仅应用于临床感染病例,而不适用于细菌定植。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验